Clinical Trial Update: GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating GI-102 alone or with pembrolizumab before surgery in patients with recurrent or progressive IDH-wildtype gl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant
• Glioblastoma Idh-wildtype
• Gliosarcoma

Drugs mentioned

• GI-102
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Status: RECRUITING